Product Description
Simnova Biotechnology is developing CART-BCMA as a treatment for multiple myeloma. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05346198)
Mechanisms of Action: CAR-T, BCMA
Novel Mechanism: No
Modality: Autologous CAR-T
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Synchroneuron Inc.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Multiple Myeloma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
CTR20201885 |
CTR20201885 | P1 |
Active, not recruiting |
Multiple Myeloma |
None |
2025-04-29 |
Patient Enrollment|Start Date|Treatments|Trial Status |